Welcome to our dedicated page for PMV Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on PMV Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a pioneering precision oncology company headquartered in Cranbury, New Jersey. Established in 2013 and formerly known as PJ Pharmaceuticals, Inc., PMV Pharmaceuticals focuses on the discovery and development of small molecule therapies specifically targeting p53 mutations, which are prevalent in approximately 50% of all human cancers.
The company’s lead product candidate, PC14586, also known as Rezatapopt, is a small molecule designed to correct and restore the function of the p53 protein. This investigational therapy has shown significant promise in addressing the TP53 Y220C mutation, which is found in about 1% of all solid tumors. The U.S. Food and Drug Administration (FDA) has granted Rezatapopt Fast Track designation for treating locally advanced or metastatic solid tumors with a TP53 Y220C mutation.
In addition to PC14586, PMV Pharmaceuticals is developing other product candidates aimed at different p53 hotspot mutations, including the p53 R273H mutation. The company is actively engaged in the PYNNACLE Phase 2 clinical trial, a registrational, tumor-agnostic trial designed to evaluate the efficacy of Rezatapopt across various cancer types.
PMV Pharmaceuticals collaborates with leading institutions like Foundation Medicine to leverage comprehensive genomic profiling for better targeting and treatment of cancer patients. Foundation Medicine’s FDA-approved tests, such as FoundationOne CDx, play a crucial role in identifying patients who may benefit from PMV Pharma’s therapies.
Financially, PMV Pharmaceuticals has reported significant milestones, including the initiation of global trials and advancements in their therapeutic pipeline. The company remains committed to transforming cancer treatment through innovative oncology solutions.
Latest News:
- Third Quarter 2023 and Recent Corporate Highlights: Media Contact: Kathy Vincent, Greig Communications (kathy@greigcommunications.com)
- PRINCETON, N.J., May 09, 2024 - PMV Pharmaceuticals reports Q1 2024 financial results and provides a corporate update.
- PMV Pharma collaborates with Foundation Medicine to develop Rezatapopt, aiming to offer new therapeutic options for high unmet medical needs.
PMV Pharmaceuticals (PMVP) has announced that initial data from its ongoing Phase 1 study of PC14586 will be presented at the 2022 ASCO Annual Meeting. This investigational therapy targets patients with advanced solid tumors featuring a p53 Y220C mutation. The oral presentation is scheduled for June 7, 2022, at 9:45 AM CDT, under the title 'First-in-human study of PC14586.' PC14586 aims to restore the normal function of p53 proteins, pivotal in cancer suppression. Detailed insights will be shared regarding its progress in the clinical trial process.
PMV Pharmaceuticals (PMVP) has made significant progress in its Phase 1/2 trial of PC14586, targeting advanced solid tumors with p53 Y220C mutations. As of December 31, 2021, the company reported a cash position of $314.1 million, down from $361.4 million in 2020. The net loss for 2021 was $57.8 million, an increase from $34.4 million in 2020, largely due to higher R&D and G&A expenses. While patient enrollment continues on track, the company anticipates initial results from the trial in mid-2022, aiming to expand its pipeline with additional p53-targeting therapies.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will participate in a panel on lung cancer at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The panel discussion is scheduled for March 9, 2022, from 9:10 AM to 10:10 AM EST. The company, focused on developing small molecule therapies targeting p53 mutations, aims to connect with institutional investors during the conference.
PMV Pharma was founded to innovate in oncology, leveraging over 40 years of research into p53 biology.
PMV Pharmaceuticals, a precision oncology company, announced that its CEO, David H. Mack, will participate in a Fireside Chat at the Guggenheim Healthcare Talks 2022 Oncology Day on February 9, 2022, at 10:30 am ET. This event will include one-on-one investor meetings, emphasizing PMV's focus on tumor-agnostic therapies targeting p53 mutants. The company is recognized for its groundbreaking work in p53 biology, established by co-founder Dr. Arnold Levine in 1979. For more details, visit PMV Pharma's website.
PMV Pharmaceuticals (Nasdaq: PMVP) announced the appointment of Kirsten Flowers to its Board of Directors, effective January 6, 2022. This change follows the resignation of Peter Thompson, M.D., who contributed to the company's growth and IPO success. Flowers brings extensive experience in oncology product launches and commercial strategy, previously serving as Chief Commercial Officer at Kura Oncology and leading Array Biopharma's first commercial launch. Her expertise is expected to enhance PMV's strategy as it advances its candidate PC14586 targeting p53 mutations.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a leader in precision oncology, announced that David H. Mack, Ph.D., will participate in a "Fireside Chat" at the Evercore ISI 4th Annual HealthCONx Conference from November 30 to December 2, 2021. The chat is scheduled for December 2, 2021, at 11:20 am ET. PMV Pharma specializes in developing small molecule therapies targeting p53 mutations, which are prevalent in about half of all cancers. This event will also include one-on-one investor meetings.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q3 2021 financial results, highlighting significant developments in its lead candidate, PC14586, targeting p53 Y220C mutations. With a robust cash position of $326.3 million as of September 30, 2021, PMVP anticipates sufficient funds to support operations through 2023. However, the company recorded a net loss of $39.5 million for the first nine months of 2021, up from $24.0 million in the same period last year, driven by increased R&D and G&A expenses.
PMV Pharmaceuticals (Nasdaq: PMVP) has appointed Tim Smith as Senior Vice President, Head of Corporate Development. Smith brings extensive experience from previous leadership roles in biotechnology, including Verseau Therapeutics and IDEAYA Biosciences. His expertise is expected to enhance PMV's efforts in developing tumor-agnostic therapies targeting p53 mutants, crucial for many cancers. The company's lead candidate, PC14586, aims to reactivate the p53 protein in patients with specific mutations.
PMV Pharmaceuticals (Nasdaq: PMVP) announced that its CEO, David H. Mack, Ph.D., will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 PM ET. The company is known for its innovative work in precision oncology, focusing on small molecule therapies targeting p53 mutants, which are implicated in nearly half of all cancers. PMV Pharma aims to revolutionize cancer treatment through its unique insights into p53 biology, established by co-founder Dr. Arnold Levine in 1979.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q2 2021 financial results, ending the quarter with $339.0 million in cash, down from $361.4 million at year-end 2020. The net loss for the six months was $24.5 million, up from $15.2 million in the same period last year. R&D expenses rose to $15.2 million, primarily due to increased clinical costs for the lead drug PC14586. Meanwhile, G&A expenses surged to $9.6 million, reflecting infrastructure costs for public operations. The company continues to enroll patients in its Phase 1/2 trial for PC14586, which targets p53 mutants in advanced solid tumors.
FAQ
What is the current stock price of PMV Pharmaceuticals (PMVP)?
What is the market cap of PMV Pharmaceuticals (PMVP)?
What does PMV Pharmaceuticals, Inc. specialize in?
What is the company's lead product candidate?
What specific mutations does PMV Pharmaceuticals target?
Has the FDA recognized any of PMV Pharmaceuticals' therapies?
What is the PYNNACLE Phase 2 clinical trial?
What collaborations has PMV Pharmaceuticals established?
Where is PMV Pharmaceuticals headquartered?
When was PMV Pharmaceuticals founded?
What recent milestones has the company achieved?
Who should I contact for more information about PMV Pharmaceuticals?
